@article{83a97f9db6734d37bfe53b190a8a6e31,
title = "Pathologic Considerations and Standardization in Mesothelioma Clinical Trials",
abstract = "The accurate diagnosis of mesothelioma is critical for the appropriate clinical management of this cancer. Many issues complicate making the diagnosis of mesothelioma including the presence of reactive mesothelial cells in benign pleural effusions, the heterogeneity of mesothelioma histopathology, the relatively high incidence of other epithelial malignancies that metastasize to the pleura, and primary sarcomas that arise within the pleura. Given the rapidly evolving field of molecular profiling and the need for translational correlates in mesothelioma clinical trials, the National Cancer Institute (NCI)–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting was convened in March 2017 to develop a consensus on standard pathology guidelines for future NCI-sponsored clinical trials in mesothelioma. This consensus statement covers recommendations for specimen handling, pathologic classification and diagnosis, biobanking, and tissue correlative studies.",
keywords = "Clinical trials, Correlatives, Mesothelioma, Pathologic classification, Pathology",
author = "Tsao, {Ming Sound} and Michele Carbone and Francoise Galateau-Salle and Moreira, {Andre L.} and Nicholson, {Andrew G.} and Roden, {Anja C.} and Adjei, {Alex A.} and Aubry, {Marie Christine} and Fennell, {Dean A.} and Daniel Gomez and David Harpole and Mary Hesdorffer and Hirsch, {Fred R.} and Geoffrey Liu and Shakun Malik and Anna Nowak and Tobias Peikert and Ravi Salgia and Peter Szlosarek and Emanuela Taioli and Haining Yang and Anne Tsao and Mansfield, {Aaron S.}",
note = "Funding Information: Dr. Mansfield is supported by NIH UL1 TR002377 , K12 CA090628 , and P30 CA015083 . Funding Information: Disclosure: Dr. Carbone has received grants from the National Institutes of Health/National Cancer Institute, DoD, V Foundation, and UH Foundation; and has a patent pending regarding BAP1, and patents issued regarding using anti-HMGB1 monoclonal antibody or other HMGB1 antibodies as a novel mesothelioma therapeutic strategy, and HMGB1 as a biomarker for asbestos exposure and mesothelioma early detection. Dr. Fennell has received grants from Roche Genentech; and has received personal fees from Roche Genentech, Bayer, Bristol-Myers Squibb, Aldeyra, MSD, and Astra Zeneca. Dr. Gomez has received grants from Bristol-Myers Squibb, Merck, and Astra Zeneca; and has received personal fees from Varian, Bristol-Myers Squibb, Merck, Astra Zeneca, and Elekta. Dr. Hirsch has received grants from Amgen, Clovis, Ventana, Bayer, Merck, and Bristol-Myers Squibb; and has received personal fees from Bristol-Myers Squibb, Genentech/Roche, Ventana, HTG Molecular Diagnostics, AbbVie, Helsinn, Astra Zeneca, Merck, Biocept, and Bayer/Loxo. Dr. Nowak has received grants from Astra Zeneca Australia; and has received personal fees from Bayer Pharmaceuticals, Roche Pharmaceuticals, Astra Zeneca, Bristol-Myers Squibb, and Boehringer Ingelheim. Dr. Peikert has participated in advisory boards for Astra Zeneca, Epizyme, and Novacure. Dr. Szlosarek has received grants from Polaris Pharma, Inc. Dr. Yang has received grants from the National Institutes of Health/National Cancer Institute, DoD, V Foundation, and Riviera United-4-a-Cure. Dr. A. Tsao has received grants from Bristol-Myers Squibb, Lilly, Millenium/Takeda, Seattle Genetics, Ariad, Boehringer Ingelheim, Polaris, Epizyme, Merck, Astra Zeneca; and has received personal fees from Bristol-Myers Squibb, Genentech/Roche, Ariad, Boehringer Ingelheim, Astra Zeneca, and Huron. Dr. Mansfield has received grants from Novartis and Verily; and has received honoraria to his institution from Genentech, AbbVie, and Bristol-Myers Squibb. The remaining authors declare no conflict of interest.Dr. Mansfield is supported by NIH UL1 TR002377, K12 CA090628, and P30 CA015083. Publisher Copyright: {\textcopyright} 2019 International Association for the Study of Lung Cancer",
year = "2019",
month = oct,
doi = "10.1016/j.jtho.2019.06.020",
language = "English (US)",
volume = "14",
pages = "1704--1717",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "10",
}